Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Helianto Farmacêutica is a prominent Brazilian company specializing in advanced wound care and dermatology solutions. Founded in 2001 and based in São José dos Campos, the company has established itself as a leader in the Brazilian market through its flagship brand, Curatec. Its extensive product portfolio includes advanced dressings such as hydrogels, calcium alginate, foam dressings, and silver-based antimicrobial treatments designed for chronic and acute wounds. In 2019, Helianto was acquired by the French healthcare group Urgo Medical, a move that integrated Helianto into a global network of healing innovation. The company operates a specialized manufacturing facility and serves a broad range of healthcare providers, including hospitals and specialized wound clinics. Helianto continues to focus on providing accessible, high-quality healing technologies to improve patient outcomes in Latin America.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Helianto Farmacêutica.